Life Sciences Companies to Share Data Sets Quickly and Securely
April 30, 2014
The life sciences and healthcare industry are in the throes of change where scientists are battling to share petabytes of sensitive data and confidential clinical information with each other without compromising on security or patient privacy. BT (News - Alert) and Ulteo have come together to help life sciences organizations create collaborative and secure analytical environments.
BT’s cloud compute platform when combined with the Ulteo open virtual desktop (OVD) will give life science companies a common platform that will allow team members to remotely access large-scale projects almost instantly. Typically such projects are time consuming and cumbersome and exchange of information may take days.
"What we've been able to create with BT is more than simply a remote desktop. It's a powerful platform that allows users to quickly access and share massive amounts of data while maintaining a firewalled, secure environment," said David Austin, VP Business Development at Ulteo.
The platform will support three desktop environments: Linux Gnome, Windows and a portal interface. Users can select the applications they want in their Web browser and open an application just as they would on their desktop. To ensure security of data, federated identity management and controls are in place. Customers can control access to data and users can view and work with data, but all information is ‘air-locked’ within the system.
This means that sensitive patient data can be accessed only as encrypted display information, and actual patient data never leaves the data center. It ensures that data always remains private.
"We know that the users of these platforms are scientists first and foremost. By making it easier for them to quickly access and share information, we are helping to create an environment where they can focus on improving their drug development pipeline,” said Yury Rozenman, business development director, BT for Life Sciences.
BT and Ulteo have a common goal. They want to allow life sciences customers focus on creating therapies that positively impact patients’ lives and at the same time honor medical privacy without having to worry about how to access and manage large amounts of data and information.
Edited by Peter Bernstein